More research is needed, but medical experts agree that cannabis plants have immense potential to slow opioid drug overdoses, which claim 115 lives every day in the U.S.
Cannabis isn't a red and blue issue in Washington. Here's how the political landscape is changing as marijuana prohibition becomes 'politically untenable.'
Innate Immunotherapeutics of Australia is the biopharmaceutical company at the center of the insider trading charges leveled against New York Rep. Chris Collins.
When investors review a drug company, pay close attention to its pharma performance, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.
A wider-than-expected quarterly loss has Echelon Wealth Partners cautious on Canopy.
Nearly two-thirds of cannabis consumers will transition to legal channels and subsequently pay more, according to a new study from Deloitte.
The U.S. markets are missing out on the rise of the cannabis industry, according to several experts TheStreet talked with on the topic.
Jim Cramer and our other experts discuss oil prices, bullish market signals and medical diagnostic plays.
Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.
When President Trump gave a speech on prescription drug pricing last week, many were disappointed pharmaceutical companies seemed to escape his wrath. The answer seems to be shame.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.